-
公开(公告)号：US12054493B2
公开(公告)日：2024-08-06
申请号：US17143326
申请日：2021-01-07
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yao-Ling Qiu , Xuri Gao , Wei Li , Hui Cao , Meizhong Jin , Jorden Kass , Xiaowen Peng , Yat Sun Or
IPC: C07D493/08 , A61K31/167 , A61K31/18 , A61K31/196 , A61K31/215 , A61K31/223 , A61K31/277 , A61K31/325 , A61K31/335 , A61K31/336 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/365 , A61K31/39 , A61K31/401 , A61K31/41 , A61K31/415 , A61K31/416 , A61K31/4164 , A61K31/421 , A61K31/426 , A61K31/439 , A61K31/44 , A61K31/4402 , A61K31/4409 , A61K31/4425 , A61K31/445 , A61K31/4545 , A61K31/5377 , A61K31/655 , C07B59/00 , C07C235/56 , C07C311/53 , C07C317/32 , C07C317/44 , C07C323/42 , C07C323/62 , C07D207/16 , C07D211/54 , C07D213/52 , C07D213/81 , C07D213/89 , C07D231/12 , C07D233/64 , C07D257/04 , C07D261/02 , C07D261/08 , C07D261/20 , C07D263/52 , C07D277/26 , C07D295/088 , C07D303/26 , C07D303/34 , C07D307/32 , C07D307/33 , C07D309/08 , C07D313/04 , C07D317/72 , C07D327/10 , C07D401/04 , C07D451/04 , C07D493/04
CPC classification number: C07D493/08 , A61K31/167 , A61K31/18 , A61K31/196 , A61K31/215 , A61K31/223 , A61K31/277 , A61K31/325 , A61K31/335 , A61K31/336 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/365 , A61K31/39 , A61K31/401 , A61K31/41 , A61K31/415 , A61K31/416 , A61K31/4164 , A61K31/421 , A61K31/426 , A61K31/439 , A61K31/44 , A61K31/4402 , A61K31/4409 , A61K31/4425 , A61K31/445 , A61K31/4545 , A61K31/5377 , A61K31/655 , C07B59/001 , C07C235/56 , C07C311/53 , C07C317/32 , C07C317/44 , C07C323/42 , C07C323/62 , C07D207/16 , C07D211/54 , C07D213/52 , C07D213/81 , C07D213/89 , C07D231/12 , C07D233/64 , C07D257/04 , C07D261/02 , C07D261/08 , C07D261/20 , C07D263/52 , C07D277/26 , C07D295/088 , C07D303/26 , C07D303/34 , C07D307/32 , C07D307/33 , C07D309/08 , C07D313/04 , C07D317/72 , C07D327/10 , C07D401/04 , C07D451/04 , C07D493/04 , C07B2200/05 , C07B2200/07 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/44 , C07C2602/46 , C07C2603/74
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R (I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.-
公开(公告)号：US11912714B2
公开(公告)日：2024-02-27
申请号：US17983501
申请日：2022-11-09
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Hui Cao , Wei Li , Xuri Gao , Jiajun Zhang , Xiaowen Peng , Jorden Kass , Ruichao Shen , Guoqiang Wang , Yat Sun Or
IPC: C07D487/10 , A61P31/14
CPC classification number: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:
which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US20230331734A1
公开(公告)日：2023-10-19
申请号：US18130641
申请日：2023-04-04
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Hui Cao , Jiajun Zhang , Xuechao Xing , Matthew C. Rhodes , Xuri Gao , Wei Li , Yat Sun Or
IPC: C07D487/10
CPC classification number: C07D487/10
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:
which inhibit picornavirus, norovirus or coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US20230295175A1
公开(公告)日：2023-09-21
申请号：US18122892
申请日：2023-03-17
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Kaicheng Zhu , Tao Wang , Xin Zhang , Xiaowen Peng , Ruichao Shen , Jiajun Zhang , Wei Li , Hui Cao , Xuri Gao , Guoqiang Wang , George G. Wu , Yat Sun Or
IPC: C07D487/10
CPC classification number: C07D487/10
Abstract: The present invention relates to processes for preparing a compound of Formula (A):
or a pharmaceutically acceptable salt or solvate thereof. Compound of Formula (A) and pharmaceutical compositions are useful as SARS-CoV-2 3CL pro inhibitors.-
公开(公告)号：US20230122228A1
公开(公告)日：2023-04-20
申请号：US17720603
申请日：2022-04-14
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Ruichao Shen , Yong He , Xuechao Xing , Matthew C. Rhodes , Joseph D. Panarese , Samuel Bartlett , Wei Li , Hui Cao , Jiajun Zhang , Xiaowen Peng , Guoqiang Wang , Yat Sun Or
IPC: C07D487/10 , A61P31/14 , A61P11/00 , A61K9/00
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
-
Patent Agency Ranking
公开(公告)号：US11339170B1
公开(公告)日：2022-05-24
申请号：US17479455
申请日：2021-09-20
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Xuri Gao , Wei Li , Jiajun Zhang , Xiaowen Peng , Hui Cao , Jorden Kass , Ruichao Shen , Guoqiang Wang , Yat Sun Or
IPC: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US10442788B2
公开(公告)日：2019-10-15
申请号：US15088517
申请日：2016-04-01
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yao-Ling Qiu , Hui Cao , Wei Li , Jorden Kass , Xuri Gao , Xiaowen Peng , Meizhong Jin , Yat Sun Or
IPC: C07D233/64 , C07D401/12 , C07F7/18 , A61K31/4164 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/55 , A61K31/553 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14 , C07F9/6558 , A61K31/4178 , A61K31/661
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y—Z-L-R1 (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US20190177320A1
公开(公告)日：2019-06-13
申请号：US16210472
申请日：2018-12-05
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yao-Ling Qiu , Xuri Gao , Xiaowen Peng , Wei Li , Jorden Kass , Hui Cao , Byung-Chul Suh , Yat Sun Or
IPC: C07D471/10 , A61P31/14 , C07D471/04 , C07D471/20
CPC classification number: C07D471/10 , A61K45/06 , A61P31/14 , C07D471/04 , C07D471/20
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US20190119288A1
公开(公告)日：2019-04-25
申请号：US16220267
申请日：2018-12-14
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yao-Ling Qiu , Hui Cao , Xiaowen Peng , Wei Li , Jorden Kass , Xuri Gao , Meizhong Jin , Yat Sun Or
IPC: C07D487/04 , A61P31/20 , A61K31/519
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US20170253609A1
公开(公告)日：2017-09-07
申请号：US15450125
申请日：2017-03-06
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yao-Ling Qiu , Xuri Gao , Wei Li , Hui Cao , Meizhong Jin , Jorden Kass , Xiaowen Peng , Yat Sun Or
IPC: C07D493/08 , A61K31/357 , C07C317/32 , A61K31/167 , A61K31/223 , C07C323/42 , C07C235/56 , C07D313/04 , A61K31/335 , C07D213/52 , A61K31/4402 , C07D213/89 , A61K31/4425 , A61K31/4409 , C07D213/81 , A61K31/44 , C07C311/53 , A61K31/18 , C07D211/54 , A61K31/445 , C07D309/08 , A61K31/351 , C07D303/34 , A61K31/336 , C07D493/04 , C07D401/04 , A61K31/4545 , C07D307/33 , A61K31/365 , C07D307/32 , A61K31/341 , A61K31/196 , A61K31/325 , A61K31/655 , A61K31/215 , C07B59/00 , C07D261/20 , A61K31/416 , C07D261/02 , A61K31/415 , C07D261/08 , C07D451/04 , A61K31/439 , C07D231/12 , C07D263/52 , A61K31/421 , C07D327/10 , A61K31/39 , C07D207/16 , A61K31/401 , C07D257/04 , A61K31/41 , C07D233/64 , A61K31/4164 , A61K31/277 , C07D277/26 , A61K31/426 , C07D295/088 , A61K31/5377 , C07D303/26 , C07D317/72
CPC classification number: C07D493/08 , A61K31/167 , A61K31/18 , A61K31/196 , A61K31/215 , A61K31/223 , A61K31/277 , A61K31/325 , A61K31/335 , A61K31/336 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/365 , A61K31/39 , A61K31/401 , A61K31/41 , A61K31/415 , A61K31/416 , A61K31/4164 , A61K31/421 , A61K31/426 , A61K31/439 , A61K31/44 , A61K31/4402 , A61K31/4409 , A61K31/4425 , A61K31/445 , A61K31/4545 , A61K31/5377 , A61K31/655 , C07B59/001 , C07B2200/05 , C07B2200/07 , C07C235/56 , C07C311/53 , C07C317/32 , C07C317/44 , C07C323/42 , C07C323/62 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/44 , C07C2602/46 , C07C2603/74 , C07D207/16 , C07D211/54 , C07D213/52 , C07D213/81 , C07D213/89 , C07D231/12 , C07D233/64 , C07D257/04 , C07D261/02 , C07D261/08 , C07D261/20 , C07D263/52 , C07D277/26 , C07D295/088 , C07D303/26 , C07D303/34 , C07D307/32 , C07D307/33 , C07D309/08 , C07D313/04 , C07D317/72 , C07D327/10 , C07D401/04 , C07D451/04 , C07D493/04
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
-
-
-
-
-
-
-
-
Search Results
72
records
(took 0.039 seconds)
